Cardiovascular disease Circulatory System Prevention of cardiovascular disease
Conditions
Interventions
Both intervention and control groups will be provided with a study medication pack, and asked to take one tablet each day. The intervention medication will contain 12.5 mg of hydrochlorothiazide, and
Sponsors
The University of Birmingham, Birmingham (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The eligible population for this pilot will include men and women between the ages of 60 and 75 (inclusive) living in Guangzhou, who attend for an ongoing cohort study, and are found to be normotensive.
Exclusion criteria
Exclusion criteria: People with existing vascular disease, clear indication or contra-indication for antihypertensive treatment and diuretics, and other chronic medical problems that would interfere with participation will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
China, England, United Kingdom
Outcome results
None listed